Gyre Therapeutics
在场
Gyre Therapeutics 是一家在股票代码 CBIO (US) 下上市的公司。
高管
查看带有其 10 名主要高管的组织结构图
Gyre Therapeutics 搜索最多的简介
高管在Gyre Therapeutics变化
- David Epstein已作为Director加入公司 (新闻发布的2024八月9号).
创建提醒
跟踪 Gyre Therapeutics 的高管变动
生物技术
Gyre Therapeutics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Gyre Therapeutics 的最新新闻稿
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card | Catalyst Biosciences
- Catalyst Biosciences Announces Support from Largest Single Stockholder | Catalyst Biosciences
- Catalyst Biosciences Publishes New Investor Presentation | Catalyst Biosciences
- Catalyst Biosciences Sends Letter to Stockholders | Catalyst Biosciences
- Catalyst Biosciences Comments on Favorable Delaware Court of Chancery Ruling | Catalyst Biosciences
- Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders | Catalyst Biosciences
- Catalyst Biosciences Sells Complement Portfolio for $60 Million | Catalyst Biosciences
- Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results | Catalyst Biosciences
- Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update | Catalyst Biosciences
- Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in Ophthalmology | Catalyst Biosciences
- View more press releases Close
通过电子邮件
